Tarlatamab before and after surgery for recurrent high-grade glioma
Treatments studied
Part of Cancer clinical trials.
This study tests a drug called tarlatamab given before and after brain surgery for people with a recurrent high-grade glioma. The goal is to see if the drug is safe and helps the body fight the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of a high-grade glioma that has returned after previous treatment.
- You must be scheduled for brain surgery to remove the tumor.
- Your doctor must confirm that you are healthy enough for surgery and the study drug.
- You cannot be taking more than 4 mg of dexamethasone (a steroid) per day.
- You cannot have an active autoimmune disease or active infections like HIV, hepatitis B, or hepatitis C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new drug called tarlatamab is safe and effective for people with certain types of brain tumors that have an IDH mutation. You may be eligible if you have had up to 2 prior treatments after the tumor returned, and you are either having surgery to remove the tumor or the tumor cannot be removed.
This study tests an investigational drug called tarlatamab in people with a rare type of cancer called neuroendocrine carcinoma that started in the female reproductive tract (cervix, vulva, or vagina). The goal is to see if tarlatamab can shrink or control the cancer. To participate, your cancer must have progressed after at least one line of platinum-based chemotherapy. You must also have measurable disease and be willing to provide a tumor sample.
This trial tests a new drug, tarlatamab, for people with small cell lung cancer that has spread to the brain. It aims to see if the drug can shrink brain tumors and help you live longer, especially if you have not had brain radiation before.
This trial tests a new combination of two drugs (tarlatamab and temozolomide) for people with certain types of aggressive brain or central nervous system tumors that have come back or not responded to standard treatment. The hope is that this combination may work better against tumors that have a specific marker called DLL3.
This trial tests a new drug called Tarlatamab for people with advanced neuroendocrine carcinoma (a rare and aggressive cancer) of the digestive system that has stopped responding to prior chemotherapy. The drug targets a protein called DLL3 found on some tumors, and researchers hope it can shrink or slow tumor growth.
This trial tests a drug called tarlatamab for people with advanced cancers that have a specific protein called DLL3. It aims to see if this treatment can help when other treatments have stopped working.
Hear when a new High-Grade Glioma (HGG) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.